Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake. The aim of the study...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Laroni, Alice, Brogi, Davide, Morra, Vincenzo Brescia, Guidi, Leonello, Pozzilli, Carlo, Comi, Giancarlo, Lugaresi, Alessandra, Turrini, Renato, Raimondi, Debora, Uccelli, Antonio, Mancardi, Giovanni Luigi
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4005629/
https://ncbi.nlm.nih.gov/pubmed/24690227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-65
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares